Preferential promotion of apoptosis of monocytes by Lactobacillus casei rhamnosus soluble factors

Clinical Nutrition

Volumn 29, Issue 1, 2010, Pages 131-140

  Chiu, Yi Han ^a   Hsieh, Yi Jen ^b,c   Liao, Kuang Wen ^a   Peng, Kou Cheng ^c  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL DONG HWA UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; IBD; Lactobacillus casei rhamnosus; Mitochondrial pathway; Monocytes; TGF

Indexed keywords

ANTIBIOPHILUS; APOPTOSIS INDUCING FACTOR; CASPASE 9; CYTOCHROME C; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; PROBIOTIC AGENT; PROCASPASE 3; PROCASPASE 9; PROTEIN BAX; PROTEIN BCL 2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; LACTOBACILLUS RHAMNOSUS; LEUKEMIA CELL LINE; LYMPHOCYTE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR WEIGHT; MONOCYTE; PROTEIN STABILITY; SUPERNATANT; THERMOSTABILITY;

ANALYSIS OF VARIANCE; APOPTOSIS; BACTERIAL PROTEINS; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; HUMANS; IN SITU NICK-END LABELING; INTESTINAL MUCOSA; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; MONOCYTES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 75949101397     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2009.07.004     Document Type: Article

References (30)

1. Bibiloni R., Fedorak R.N., Tannock G.W., Madsen K.L., Gionchetti P., Campieri M., et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005, 100:1539-1546.
2. Miele E., Pascarella F., Giannetti E., Quaglietta L., Baldassano R.N., Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009, 104:437-443.
3. Kruis W., Fric P., Pokrotnieks J., Lukás M., Fixa B., Kascák M., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli nissle 1917 is as effective as with standard mesalazine. Gut 2004, 53:1617-1623.
4. Marteau P., Lémann M., Seksik P., Laharie D., Colombel J.F., Bouhnik Y., et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006, 55:842-847.
5. Bousvaros A., Guandalini S., Baldassano R.N., Botelho C., Evans J., Ferry G.D., et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005, 11:833-839.
6. Guzy C., Paclik D., Schirbel A., Sonnenborn U., Wiedenmann B., Sturm A. The probiotic Escherichia coli strain Nissle 1917 induces γδ T cell apoptosis via caspase- and FasL-dependent pathways. Int Immunol 2008, 20:829-840.
7. Iyer C., Kosters A., Sethi G., Kunnumakkara A.B., Aggarwal B.B., Versalovic J. Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-κB and MAPK signaling. Cell Microbiol 2008, 10:1442-1452.
8. Yan F., Cao H., Cover T.L., Whitenead R., Washington M.K., Polk D.B. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007, 132:562-575.
9. Lügering A., Lebiedz P., Koch S., Kucharzik T. Apoptosis as a therapeutic tool in IBD?. Ann N Y Acad Sci 2006, 1072:62-77.
10. Itoh J., de La Motte C., Strong S.A., Levine A.D., Fiocchi C. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut 2001, 49:35-41.
11. McGuckin M.A., Eri R., Simms L.A., Florin T.H., Radford-Smith G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 2008, 15:100-113.
12. Strober W., Fuss I.J., Blumberg R.S. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002, 20:495-549.
13. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
14. Lin J.S., Chiu Y.H., Lin N.T., Chu C.H., Huang K.C., Liao K.W., et al. Different effects of probiotic species/strains on infections in preschool children: a double-blind, randomized, controlled study. Vaccine 2009, 27:1073-1079.
15. Lin C.F., Lei H.Y., Shiau A.L., Liu H.S., Yeh T.M., Chen S.H., et al. Endothelial cell apoptosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide. J Immunol 2002, 169:657-664.
16. Cossarizza A., Ceccarelli D., Masini A. Functional heterogeneity of an isolated mitochondrial population revealed by cytofluorometric analysis at the single organelle level. Exp Cell Res 1996, 222:84-94.
17. Luethviksson B.R., Gunnlaugsdottir B. Transforming growth factor-beta as a regulator of site-specific T-cell inflammatory response. Scand J Immunol 2003, 58:129-138.
18. Heldin C.H., Miyazono K., ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390:465-471.
19. Chang W.H., Liu J.J., Chen C.H., Huang T.S., Lu F.J. Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by fermented soy milk. Nutr Cancer 2002, 43:214-226.
20. Lügering A., Schmidt M., Lügering N., Pauels H.G., Domschke W., Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145-1157.
21. Baert F.J., D'Haens G.R., Peeters M., Hiele M.I., Schaible T.F., Shealy D., et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999, 116:22-28.
22. Sabatino A.D., Ciccocioppo R., Cinque B., Millimaggi D., Morera R., Ricevuti L., et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004, 53:70-77.
23. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
24. Lin P.W., Nasr T.R., Berardinelli A.J., Kumar A., Neish A.S. The probiotic Lactobacillus GG may augment intestinal host defense by regulating apoptosis and promoting cytoprotective responses in the developing murine gut. Pediatr Res 2008, 64:511-516.
25. Rutgeerts P., Van Assche G., Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004, 126:1593-1610.
26. Van den Brande J.M., Braat H., van den Brink G.R., Versteeg H.H., Bauer C.A., Hoedemaeker I., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124:1774-1785.
27. Letterio J.J., Roberts A.B. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998, 16:137-161.
28. Kader H.A., Tchernev V.T., Satyaraj E., Lejnine S., Kotler G., Kingsmore S.F., et al. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-β1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol 2005, 100:414-423.
29. von der Weid T., Bulliard C., Schiffrin E.J. Induction by a lactic acid bacterium of a population of CD4(+) T cells with low proliferative capacity that produce transforming growth factor beta and interleukin-10. Clin Diagn Lab Immunol 2001, 8:695-701.
30. Christensen H.R., Frøkiaer H., Pestka J.J. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol 2002, 68:171-178.